Bisphosphonate-associated osteonecrosis of the jaws - report of three cases in bulgaria and review of the literature

Acta Clinica Croatica

Volumn 50, Issue 2, 2011, Pages 273-279

  Pechalova, Petia ^a   Bakardjiev, Angel ^b   Zaprianov, Zaprian ^c   Vladimirov, Boyan ^a   Poriazova, Elena ^c   Zheleva, Anastasia ^a   Hadjigeorgiev, Georgi ^c   Goranova Marinova, Vesselina ^a   Goranov, Stefan ^a  

^a MEDICAL UNIVERSITY OF PLOVDIV   (Bulgaria)

^b Faculty of Dental Medicine   (Bulgaria)

^c Department of Pathology ^*  (Bulgaria)

Author keywords

Adverse effects; Bisphosphonates; Chemically induced; Jaw diseases; Osteonecrosis; Surgery; Surgical operative procedures

Indexed keywords

ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ADULT; AGED; BULGARIA; CANCER CHEMOTHERAPY; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; DEBRIDEMENT; ENDOMETRIOID CARCINOMA; FEMALE; HUMAN; JAW OSTEONECROSIS; JAW PAIN; MALE; OSTEOLYSIS; PANORAMIC RADIOGRAPHY; PROSTATE CARCINOMA; REVIEW; WOUND HEALING; ARTICLE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY;

AGED; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED;

EID: 84856625297     PISSN: 03539466     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. BAGAN JV, MURILLO J, JIMENEZ Y, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 2005;34:120-3.
2. BILEZIKIAN JP. Osteonecrosis of the jaw - do bisphosphonates pose a risk? N Engl J Med 2006;2278-81.
3. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of The Jaws. J Oral Maxillofac Surg 2007;65:369-76.
4. BAMIAS A, KASTRITIS E, BAMIA C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-7.
5. BOONYAPAKORN T, SCHIRMER I, REICHART PA, et al. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 2008;44:857-69.
6. STOCKMANN P, VAIRAKTARIS E, WEHRHAN F, SEISS M, et al. Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up. Support Care Cancer 2010;18:449-60.
7. TASSINARI D, POGGI B, NICOLETTI S, et al. Zoledronic acid treatment at home: safety data from an observational prospective trial. J Palliat Med 2007;10:352-8.
8. VESCOVI P, MERIGO E, MELETI M, et al. Nd:YAG laser biostimulation of bisphosphonate-associated necrosis of the jawbone with and without surgical treatment. Br J Oral Maxillofac Surg 2007;45:628-33.
9. WUTZL A, BIEDERMANN E, WANSCHITZ F, et al. Treatment results of bisphosphonate-related osteonecrosis of the jaws. Head Neck 2008;30:1224-30.
10. WOO SOOK-BIN, HELLSTEIN JW, KALMAR JR. Systematic review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61.
11. ROGERS MJ, RUSSEL RG. Overview of bisphosphonates. Cancer 1997;80:1652-60.
12. WANG J, POGREL MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003;61:1104-7.
13. CHAPURLAT RD, DELMAS PD, LIENS D, et al. Longterm effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res 1997;10:1746-52.
14. LARA R, MATARAZZO P, BERTELLONI S, et al. Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome. Acta Paediatr 2000;89:188-93.
15. TARASOFF P, CSERMAK K. Avascular necrosis of the jaws: risk factor in metastatic cancer patients. J Oral Maxillofac Surg 2003;61:1238-9.
16. WARNKE PH, SPRINGER IN, RUSSO PA, et al. Innate immunity in human bone. Bone 2006;38:400-8.
17. DANNEMANN C, GRATZ KW, ZWABLEN R. Clinical experiences with bisphosphonates-induced osteochemonecrosis of the jaws. Swiss Med Week 2006;136:504-9.
18. CORSO A, VARETTONI M, ZAPPASODI P, et al. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 2007;21:1545-8.
19. FAVIA G, PILOLLI GP, MAIORANO E. Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy. Bone 2009;45:406-13.
20. BADROS A, WEIKKEL D, SALAMA A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006;24:945-52.
21. MARX RE, SAWATARI Y, FORTIN M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg 2005;63:1567-75.
22. DUNSTAN CR, FELSENBERG D, SEIBEL MJ. Therapy insight: the risk and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol 2007;4:42-55.
23. MIGLIORATI CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 2003;21:4253.
24. RUGGIERO SL, MEHROTRA B, ROSSENBERG TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34.
25. GRAZIANI F, CEI S, LA FERLA F, et al. Association between osteonecrosis of the jaws and chronic high-dosage intravenous bisphosphonate therapy. J Craniofac Surg 2006;17:876-9.
26. MAVROKOKKI T, CHENG A, STEIN B. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415-23.
27. NASTRO E, MUSOLIN C, ALLEGRA A, et al. Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer. Acta Haematol 2007;117:181-7.